Singapore markets open in 2 hours 31 minutes

NeuroSense Therapeutics Ltd. (NRSN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.6000-0.0500 (-3.03%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.6500
Open1.5601
Bid1.5800 x 100
Ask1.6500 x 100
Day's range1.5601 - 1.6400
52-week range0.4000 - 2.3300
Volume72,130
Avg. volume310,954
Market cap27.734M
Beta (5Y monthly)1.56
PE ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings date25 May 2024 - 29 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.25
  • PR Newswire

    NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

    NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School, will be presenting data from the PARADIGM Phase 2 study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting.

  • PR Newswire

    NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

    NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 2,980,000 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent priv

  • PR Newswire

    NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

    Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases, announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS.